Pilot Trial of Transversus Abdominis Plane Ropivacaine Infusions following Abdominal Surgery
The Analgesic Efficacy of Ultrasound Guided Transversus Abdominis Plane Ropivacaine Continuous Blockade in Patients Undergoing Abdominal Surgery - Pilot Trial
Western Health
20 participants
Aug 1, 2008
Interventional
Conditions
Summary
This is a pilot trial looking at the safety and feasability of running a local anaesthetic infusion to improve the post-operative pain relief of patients who have had abdominal surgery. The local anaesthetic, called ropivacaine, will be run via a transversus abdominis plane catheter. This will be placed in both sides of the abdomen between two muscle layers. The study will look at the effect of the infusion on how much morphine the patient requires after their surgery. The study will also look at the levels of ropivacaine in the blood during the infusion, which will run for three days.
Eligibility
Inclusion Criteria2
- Age over 18 years
- Elective or semi-elective abdominal surgery requiring mid-line incision
Exclusion Criteria1
- Patient refusal Acute abdomen A clinical history consistent with opioid tolerance including preoperative opioid consumption of longer than one week, intravenous opioid drug use Preoperative use of opioid antagonists like buprenorphine and naltrexone A clinical history of chronic pain, where patients may benefit from early commencement of agents like ketamine Renal impairment with creatinine clearance less than 60 mL/min Drug allergy or contraindication to morphine, ropivacaine, paracetamol Anaesthetist preference for placement of central neuroaxial blockade/catheter Surgeon refusal to placement of catheters Inability of patient to use patient controlled analgesia pump post-operatively or to understand grading of pain via verbal pain score, laparoscopic assisted surgery
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Transversus abdominis plane infusion using ropivacaine 0.2%, 0.1mL/kg/hr bilaterally. Infusion rate rounded down to the nearest integer. Maximum of 7mL/h bilaterally. 72 hr duration of infusion.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12608000291381